Whole Genome Sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors.

Mridula George¹, Gary S Schwartz², Wassim McHayleh³, Vitaly Margulis⁴, Hideaki Bando⁵, Takayuki Yoshino⁵, George Ansstas⁶, Carly Bess Scalise⁷, Sumedha Sudhaman⁷, Arkarachai Fungtammasan⁷, Bharat Sridhar⁷, Jordan Feeney⁷, Himanshu Sethi⁷, Morgan M Quail⁷, Sharlene Velichko⁷, Wilson Tan⁷, Alexander Hsieh⁷, Anastasia Butskova⁷, Ryan Ptashkin⁷, Carcia Carson⁷, Ashley Wray⁷, Charuta C Palsuledesai⁷, Meenakshi Malhotra⁷, Ahmet Zehir⁷, Eser Kirkizlar⁷, Matthew Rabinowitz⁷, Ryan K Swenerton⁷, Gabrielle Heilek⁷, Adham Jurdi⁷, Adam C ElNaggar⁷, Michael Krainock⁷, Caitlin A Schonewolf⁷, Angel A Rodriguez⁷, Shruti Sharma⁷, Ekaterina Kalashnikova⁷, Minetta C Liu⁷, Alexey Aleshin⁷, Matthew D Galsky⁸

¹Rutgers Cancer Institute, New Brunswick, New Jersey, USA.

²Baylor University Medical Center, Dallas, TX, USA.

³Advent Health Cancer Institute, Altamonte Springs, Orlando, FL, USA.

⁴UT Southwestern Medical Center, Dallas, TX, USA.

⁵National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

⁶Washington University School of Medicine in St. Louis, St. Louis, MO, USA.

⁷Natera, Inc. Austin, TX, USA.

⁸Mount Sinai Health System/ Icahn School of Medicine at Mount Sinai, New York, NY, USA.

PubMed DOI

Abstract

BACKGROUND: Circulating tumor DNA (ctDNA) assays can transform patient management by enabling molecular residual disease (MRD) detection, prognosis prediction, and treatment monitoring. Here, we report clinical performance of Signatera™ Genome, a whole genome sequencing (WGS)-based ctDNA assay, in a diverse pan-cancer cohort at landmark and longitudinal settings post-definitive treatment. METHODS…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.